Table 1. Summary of retrospective (n>200) and prospective trials evaluating SBRT-outcomes.
| Study | Year | No. of cases | Fractionation | Tox. grade pneumonitis/rib fracture [%] | OS 3a (%) | CSS 3a (%) | LC 3a (%) | Median follow up |
|---|---|---|---|---|---|---|---|---|
| Retrospective | ||||||||
| Onishi (30) | 2004 | 245 | ≥2 [6.5/0.8] | 56 | 78 | 86.5 | 24 | |
| Onishi (31) | 2007 | 257 | ≥2 [5.4/1.6] | 56.8 | 76.9 | 86 | 38 | |
| Grills SBRT (32) | 2012 | 505 | ≥3 [2/1] | 48 | 77 | 91 | 30 | |
| Senthi (33) | 2013 | 676 | 55 [2a] | – | 95 [2a] | 33 | ||
| Guckenberger (34) | 2013 | 582 | ≥2 [7/4] | 49 | 80 | 21 | ||
| Prospective | ||||||||
| Nagata (35) | 2005 | 45 | 4×12 Gy (at isocenter) | >3 [0] | 72 (stage IB) | – | 98 | 30 |
| Baumann (36) | 2009 | 57 | 3×15 Gy (67% isodose) | ≥3 [29.8] | 60 | 88 | 92 | 35 |
| Fakiris (37) | 2009 | 70 | 60-66 Gy in 3 fractions (80% Isodose) | ≥3 [15.7] | 42.7 | 81.7 | 88.1 | 50 |
| Timmerman (38,39) | 2009 | 55 | 3×18 Gy | ≥3 [16.3] | 55.8 | – | 97.6 | 34 |
| Bral (40) | 2011 | 40 | 60 Gy in 3-4 fractions | ≥3 [20] | 52 [2a] | 64 [2a] | 84 [2a] | 16 |
| Ricardi (41) | 2010 | 62 | 3×15 Gy (80% isodose) | ≥3 [3.2/1.6] | 57.1 | 72.5 | 87.8 | 28 |
SBRT, stereotactic-body-radiotherapy; OS, overall survival; CSS, cause-specific survival; LC, local control; 3a, 3-year-value; 2a, 2-year-value.